Novo Holdings A/S - 09 Feb 2024 Form 4 Insider Report for Metagenomi, Inc. (MGX)

Role: 10%+ Owner
Signature: /s/ Barbara Fiorini Due, General Counsel, Finance & Operations
Issuer symbol: MGX
Transactions as of: 09 Feb 2024
Net transactions value: +$13,025,000
Form type: 4
Filing time: 15 Feb 2024, 20:38:42 UTC
Previous filing: 08 Feb 2024
Next filing: 18 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MGX	COMMON STOCK	Purchase	$1,025,000	+100,000		$10.25^*	100,000	09 Feb 2024	Direct
transaction	MGX	COMMON STOCK	Conversion of derivative security		+839,175	+839%		939,175	13 Feb 2024	Direct	F1
transaction	MGX	COMMON STOCK	Purchase	$12,000,000	+800,000	+85%	$15.00^*	1,739,175	13 Feb 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MGX	SERIES B PREFERRED STOCK	Conversion of derivative security		-147,415	-100%		0	13 Feb 2024	COMMON STOCK	147,415		Direct	F1
transaction	MGX	SERIES B-1 PREFERRED STOCK	Conversion of derivative security		-691,760	-100%		0	13 Feb 2024	COMMON STOCK	691,760		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Novo Holdings A/S is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.
F2	Represents a purchase from the underwriters in the Issuer's initial public offering.